304 related articles for article (PubMed ID: 21527517)
21. The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
Senkevitch E; Durum S
Cytokine; 2017 Oct; 98():33-41. PubMed ID: 28277287
[TBL] [Abstract][Full Text] [Related]
22. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
23. A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.
Qiu X; Guo G; Chen K; Kashiwada M; Druker BJ; Rothman PB; Chen JL
Neoplasia; 2012 Jun; 14(6):547-58. PubMed ID: 22787435
[TBL] [Abstract][Full Text] [Related]
24. JAK/STAT signalling mediates cell survival in response to tissue stress.
La Fortezza M; Schenk M; Cosolo A; Kolybaba A; Grass I; Classen AK
Development; 2016 Aug; 143(16):2907-19. PubMed ID: 27385008
[TBL] [Abstract][Full Text] [Related]
25. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
[TBL] [Abstract][Full Text] [Related]
26. Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.
Gaikwad A; Prchal JT
Exp Hematol; 2007 Nov; 35(11):1647-56. PubMed ID: 17976517
[TBL] [Abstract][Full Text] [Related]
27. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
[TBL] [Abstract][Full Text] [Related]
28. IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling.
Subotički T; Mitrović Ajtić O; Beleslin-Čokić BB; Bjelica S; Djikić D; Diklić M; Leković D; Gotić M; Santibanez JF; Noguchi CT; Čokić VP
Cell Biol Int; 2019 Feb; 43(2):192-206. PubMed ID: 30571852
[TBL] [Abstract][Full Text] [Related]
29. Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms.
Čokić VP; Mitrović-Ajtić O; Beleslin-Čokić BB; Marković D; Buač M; Diklić M; Kraguljac-Kurtović N; Damjanović S; Milenković P; Gotić M; Raj PK
Mediators Inflamm; 2015; 2015():453020. PubMed ID: 26491227
[TBL] [Abstract][Full Text] [Related]
30. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
[TBL] [Abstract][Full Text] [Related]
31. Enhancer of Polycomb and the Tip60 complex repress hematological tumor initiation by negatively regulating JAK/STAT pathway activity.
Bailetti AA; Negrón-Piñeiro LJ; Dhruva V; Harsh S; Lu S; Bosula A; Bach EA
Dis Model Mech; 2019 May; 12(5):. PubMed ID: 31072879
[TBL] [Abstract][Full Text] [Related]
32. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
[TBL] [Abstract][Full Text] [Related]
33. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.
Staerk J; Kallin A; Demoulin JB; Vainchenker W; Constantinescu SN
J Biol Chem; 2005 Dec; 280(51):41893-9. PubMed ID: 16239216
[TBL] [Abstract][Full Text] [Related]
34. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.
Wang Y; Fiskus W; Chong DG; Buckley KM; Natarajan K; Rao R; Joshi A; Balusu R; Koul S; Chen J; Savoie A; Ustun C; Jillella AP; Atadja P; Levine RL; Bhalla KN
Blood; 2009 Dec; 114(24):5024-33. PubMed ID: 19828702
[TBL] [Abstract][Full Text] [Related]
35. A role for JAK2 mutations in myeloproliferative diseases.
Morgan KJ; Gilliland DG
Annu Rev Med; 2008; 59():213-22. PubMed ID: 17919086
[TBL] [Abstract][Full Text] [Related]
36. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
37. Mining for JAK-STAT mutations in cancer.
Constantinescu SN; Girardot M; Pecquet C
Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
[TBL] [Abstract][Full Text] [Related]
38. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
Calvisi DF; Ladu S; Gorden A; Farina M; Conner EA; Lee JS; Factor VM; Thorgeirsson SS
Gastroenterology; 2006 Apr; 130(4):1117-28. PubMed ID: 16618406
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis.
Zhang Y; Dees C; Beyer C; Lin NY; Distler A; Zerr P; Palumbo K; Susok L; Kreuter A; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2015 May; 74(5):936-43. PubMed ID: 24431397
[TBL] [Abstract][Full Text] [Related]
40. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]